TOP1 and cancer: Targeted inhibition of RNR activity in cancer cells defective for RNase H2 might hyper-sensitize them to PARP-trapping drugs, which hamper the repair of TOP1-mediated DNA lesions at sites of single genomic rNMPs (108,114,115).